NasdaqGS:CYTKBiotechs
Cytokinetics (CYTK) Is Up 29.9% After Positive Aficamten Phase 3 Data and Regulatory Progress
In late August 2025, Cytokinetics presented new clinical data for aficamten at the European Society of Cardiology Congress in Madrid, with findings published in key medical journals and updates on its regulatory review status in major markets including the U.S., Europe, and China.
A unique highlight from this announcement was that aficamten showed a minimal incidence of new atrial fibrillation and is accompanied by plans for commercialization, reinforced by the appointment of an experienced...